Immune Effects

Boswellia/AKBA's immune activity is not simply "anti-inflammatory." It is a selective inflammatory re-programmer — suppressing the chronic, tumour-promoting inflammatory signals that help cancer survive and evade immune clearance, while preserving or supporting the acute immune responses required for immune cells to recognise and kill tumour cells. Understanding which mediators it affects, and why that matters in the anti-tumour immune cycle, is what makes this compound genuinely interesting beyond its direct anti-cancer mechanisms.

The Two Faces of Inflammation in Cancer

Before naming the specific mediators, the framework matters. Chronic low-grade inflammation driven by NF-κB, COX-2, and 5-LOX creates a tumour microenvironment (TME) that actively suppresses the immune system's ability to kill cancer cells. It does this by:

• Recruiting and polarising tumour-associated macrophages (TAMs) toward an M2 (immunosuppressive) phenotype

• Elevating IL-6 and IL-10, which suppress cytotoxic T cell and NK cell activity

• Driving TNF-α at chronic low levels, which paradoxically promotes tumour survival rather than tumour death at sustained sub-acute concentrations

• Producing PGE2 (prostaglandin E2, via COX-2), which directly suppresses NK cell and T cell function in the TME

AKBA's suppression of NF-κB, COX-2, 5-LOX, and the downstream mediators these pathways produce directly dismantles each of these immunosuppressive mechanisms.

Specific Inflammatory Mediators Suppressed by AKBA

TNF-α (Tumour Necrosis Factor-alpha)

• Suppressed by AKBA in a concentration-dependent manner — confirmed by ELISA assay at 2.5, 5, and 10 μM (P < 0.001 for all concentrations).

• Also confirmed at the mRNA level by qPCR, showing AKBA suppresses TNF-α gene transcription, not just protein secretion.

• Why it matters in cancer: Chronic TNF-α in the TME supports tumour cell survival via NF-κB pro-survival signalling and promotes immunosuppressive M2 macrophage polarisation. AKBA breaks this cycle.

IL-1β (Interleukin-1 beta)

• Suppressed concentration-dependently at the protein and mRNA levels (P < 0.001)

• Why it matters in cancer: IL-1β drives VEGF-mediated angiogenesis, promotes epithelial-to-mesenchymal transition (EMT), and creates an inflammatory TME that suppresses cytotoxic T cell infiltration. It is particularly elevated in pancreatic cancer, colorectal cancer, and breast cancer. Its suppression by AKBA simultaneously reduces both tumour-promoting inflammation and immune evasion signals.

IL-6 (Interleukin-6)

• Suppressed concentration-dependently at protein (ELISA) and gene expression (qPCR) levelpmc.ncbi.nlm.nih+1

• Why it matters in cancer: IL-6 is one of the most well-documented drivers of immune evasion in cancer. It activates STAT3 in tumour cells (driving proliferation and survival), promotes M2 macrophage polarisation, suppresses dendritic cell maturation, and inhibits cytotoxic T lymphocyte (CTL) differentiation. IL-6 is chronically elevated in glioblastoma, breast, ovarian, colorectal, and prostate cancer and correlates with worse prognosis. AKBA's suppression of both IL-6 and STAT3 (via PI3K/Akt inhibition) provides dual-pathway blockade of this axis.

COX-2 → PGE2 (Prostaglandin E2)

• COX-2 gene expression was suppressed at the mRNA level by AKBA, concentration-dependently (P < 0.001)

• PGE2 protein levels were directly suppressed by AKBA (confirmed by ELISA)

• Why it matters in cancer: PGE2 is arguably the single most immunosuppressive lipid mediator in the TME. It directly suppresses NK cell cytotoxicity, impairs dendritic cell function, drives regulatory T cell (Treg) expansion, and promotes M2 macrophage polarisation. Every major immunosuppressive arm of the TME is partly COX-2/PGE2 driven. AKBA's dual suppression of COX-2 gene expression and PGE2 protein is therefore among its most clinically significant immune contributions.pmc.ncbi.nlm.nih+1

iNOS (Inducible Nitric Oxide Synthase)

• Gene expression suppressed by AKBA at mRNA level (P < 0.001)[pmc.ncbi.nlm.nih]​

• Why it matters in cancer: iNOS-derived nitric oxide (NO) at high concentrations in the TME has complex effects — including suppression of T cell and NK cell function, promotion of tumour blood vessel formation, and contribution to genomic instability in tumour cells. Chronic iNOS-driven NO is immunosuppressive and pro-tumour. Its suppression removes a further source of TME-driven immune evasion.

IFN-γ (Interferon-gamma)

• AKBA reduces elevated IFN-γ in the context of LPS-induced acute systemic inflammation.

• Why this requires careful interpretation: IFN-γ is the primary activating cytokine for cytotoxic immune responses against cancer (it activates NK cells, CTLs, and M1 macrophages). Its reduction by AKBA in hyper-inflammatory contexts reflects appropriate immune tempering rather than immunosuppression of the anti-tumour response. In a chronic TME context, IFN-γ production by NK cells and CTLs is often already suppressed by the IL-6/PGE2/IL-10 environment — AKBA's net effect of removing those suppressors is pro-IFN-γ in the anti-tumour context. This nuance is important: AKBA is not a broad IFN-γ suppressor; it is an acute inflammatory modulator.

IL-10 (Interleukin-10)

• AKBA increases IL-10 compared to LPS-treated inflammatory conditions.

• Why it matters: In a chronic TME context, elevated IL-10 sounds counterintuitive (IL-10 is immunosuppressive). However, in the specific context of resolving acute LPS-driven hyperinflammation, IL-10 rise is part of appropriate immune resolution. In the TME, the balance is complex — but the increase here reflects AKBA's capacity to shift the immune microenvironment from pathological chronic inflammation toward resolved, regulated inflammation that creates space for effective anti-tumour immune activity rather than exhausted immune cells unable to function in a chronically inflamed environment.

LTB4 (Leukotriene B4) via 5-LOX

• AKBA directly inhibits 5-LOX with an IC50 of 1.5 μM in human neutrophils (non-redox, non-competitive inhibition) — the most potent 5-LOX inhibitory activity of all boswellic acids.

• Important pharmacokinetic caveat: In the presence of albumin (10 mg/mL), 11-keto boswellic acid's 5-LOX inhibition was abolished in whole blood assays — attributed to >95% albumin binding. This means bioavailability and formulation quality directly determine whether 5-LOX inhibition translates in vivo.

• Why it matters in cancer: LTB4 is a potent chemoattractant that recruits immunosuppressive myeloid cells and mast cells into the TME. It promotes tumour angiogenesis and has direct proliferative effects on certain cancer cell types (prostate, colorectal). 5-LOX inhibition by AKBA is a mechanism curcumin and polydatin do not share — it is a genuinely unique contribution to the anti-inflammatory combination stack.

How This Translates to the Anti-Tumour Immune Cycle

The cancer-immunity cycle — from tumour antigen release through to CTL-mediated cancer cell killing — fails at multiple points in established tumours. Here is where AKBA's specific mediator suppression intervenes:

Macrophage and Dendritic Cell Effects

Macrophage polarisation: AKBA modulates macrophage inflammatory behaviour, confirmed in a 2024 CNS Neuroscience & Therapeutics study showing AKBA modulates macrophage polarisation and neuroinflammation. In the context of the TME, where M2-polarised TAMs are a primary driver of immune evasion and treatment resistance, the removal of key M2-polarising signals (IL-6, IL-10 at pathological levels, PGE2) by AKBA represents a meaningful shift toward immune competence.

Dendritic cells: AKBA inhibits the secretion of pro-inflammatory cytokines (TNF-α, IL-12, IL-23, IL-22, IL-1β) by mature dendritic cells in hyperinflammatory contexts — while the broader evidence suggests that by removing chronic TME inflammatory suppression, DC maturation and antigen presentation capacity is net-improved in the tumour context. This apparent paradox (AKBA reduces DC cytokine output in hyperinflammatory conditions but supports DC function in a tumour context) reflects the same context dependence seen across all its mechanisms.

Overall Immune Impact: SELECTIVE INFLAMMATORY RE-PROGRAMMER

References for Immune Effects

• AKBA prevents inflammation via suppression of TNF-α, IL-1β, IL-6, PGE2, COX-2 and iNOS — PMC 2022 — https://pmc.ncbi.nlm.nih.gov/articles/PMC8986374/

• AKBA suppresses colitis-associated colorectal cancer and reduces TNF-α, IFN-γ, IL-12p70, IL-1β; increases IL-10 — PMC 2025 — https://pmc.ncbi.nlm.nih.gov/articles/PMC12308244/

• From bench to bedside: boswellic acids in anti-inflammatory therapy — 5-LOX IC50, NF-κB mechanism, cytokine panel — PMC 2025 — https://pmc.ncbi.nlm.nih.gov/articles/PMC12669112/

• AKBA modulates macrophage polarisation — CNS Neuroscience & Therapeutics, 2024 — https://onlinelibrary.wiley.com/doi/full/10.1111/cns.14642

• AKBA inhibits cytokine secretion by dendritic cells — https://www.sciencedirect.com/science/article/abs/pii/S0024320518303126

• T cells, NK cells, and TAMs in anti-tumour immune cycles — Yang et al., 2023 — https://pubmed.ncbi.nlm.nih.gov/37457707/

• NK cell anti-tumour activity and macrophage interaction — Frontiers in Immunology, 2025 — https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1656925/full

Jump to another Boswellia page

Core pages

• Boswellia in Oncology Overview

• Evidence Summary

• Anticancer Mechanisms

• Boswellia Evidence by Cancer Type

Mechanism deep dives

• Redox Dual Action

• NRF2 Impact

• Ferroptosis Findings

• Immune Effects

Practical pages

• Pharmacokinetics & Metabolism

• Safety & Interactions

• Synergistic Combinations

• Hydroxychloroquine + Boswellia

• Dosing & Timing

• Sourcing Quality Boswellia

Cancer-type pages

• Glioblastoma & Brain Tumours

• Breast Cancer

• Colorectal Cancer

• Pancreatic Cancer

• Prostate Cancer

• Non-Small Cell Lung Cancer

• Ovarian Cancer

• Other Cancer Types